Epizyme, Inc. (NASDAQ:EPZM) Stock Holdings Raised by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC raised its stake in Epizyme, Inc. (NASDAQ:EPZM – Get Rating) by 15,428.6% in the 1st quarter, Holdings Channel.com reports. The firm owned 163,050 shares of the biopharmaceutical company's stock after acquiring an additional 162,000 shares during the period. Nisa Investment Advisors LLC's holdings in Epizyme were worth $188,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Primecap Management Co. CA increased its position in shares of Epizyme by 0.4% in the 4th quarter. Primecap Management Co. CA now owns 15,366,477 shares of the biopharmaceutical company's stock worth $38,416,000 after purchasing an additional 56,100 shares during the last quarter. Assenagon Asset Management S.A. increased its position in shares of Epizyme by 459.5% in the 1st quarter. Assenagon Asset Management S.A. now owns 3,225,145 shares of the biopharmaceutical company's stock worth $3,709,000 after purchasing an additional 2,648,661 shares during the last quarter. Bank of America Corp DE increased its position in shares of Epizyme by 6,665.3% in the 4th quarter. Bank of America Corp DE now owns 2,955,970 shares of the biopharmaceutical company's stock worth $7,390,000 after purchasing an additional 2,912,277 shares during the last quarter. Northern Trust Corp grew its position in shares of Epizyme by 1.3% during the 4th quarter. Northern Trust Corp now owns 948,546 shares of the biopharmaceutical company's stock valued at $2,372,000 after buying an additional 12,285 shares during the last quarter. Finally, BNP Paribas Arbitrage SA grew its position in shares of Epizyme by 2,847.3% during the 4th quarter. BNP Paribas Arbitrage SA now owns 482,794 shares of the biopharmaceutical company's stock valued at $1,207,000 after buying an additional 466,413 shares during the last quarter. Institutional investors own 76.45% of the company's stock.

Get Epizyme alerts:

Analyst Upgrades and Downgrades

EPZM has been the subject of a number of recent research reports. HC Wainwright lowered their price objective on shares of Epizyme from $8.00 to $6.00 and set a "buy" rating for the company in a research report on Friday, June 3rd. Cowen downgraded shares of Epizyme from an "outperform" rating to a "market perform" rating and set a $1.50 price objective for the company. in a research report on Monday, June 27th. Cowen downgraded shares of Epizyme from an "outperform" rating to a "market perform" rating and set a $1.50 price objective for the company. in a research report on Monday, June 27th. Wedbush downgraded shares of Epizyme from an "outperform" rating to a "neutral" rating in a research report on Monday, June 27th. Finally, StockNews.com raised shares of Epizyme from a "sell" rating to a "hold" rating in a research report on Monday. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $3.50.

Epizyme Stock Up 0.7 %

Epizyme stock opened at $1.49 on Thursday. The firm has a 50-day moving average price of $1.01 and a two-hundred day moving average price of $1.18. The firm has a market capitalization of $250.81 million, a price-to-earnings ratio of -0.70 and a beta of -0.44. Epizyme, Inc. has a 52-week low of $0.41 and a 52-week high of $7.01.

Epizyme (NASDAQ:EPZM – Get Rating) last posted its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.04). The firm had revenue of $8.70 million for the quarter, compared to analyst estimates of $10.86 million. Epizyme had a negative net margin of 614.08% and a negative return on equity of 2,459.33%. During the same period in the previous year, the firm earned ($0.69) earnings per share. Research analysts expect that Epizyme, Inc. will post -1.38 earnings per share for the current year.

Epizyme Company Profile

(Get Rating)

Epizyme, Inc, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients.

Featured Stories

• Get a free copy of the StockNews.com research report on Epizyme (EPZM)
• The MarketBeat Podcast: Portfolio Management in Market Downturns
• Can These Two Airline Stocks Overcome Gravity And Fly Higher?
• Shopify Stock Rallies Despite Quarterly Loss
• Two Automation Stocks The Institutions Are Buying
• Can Owens-Corning Insulate Your Portfolio?

Want to see what other hedge funds are holding EPZM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Epizyme, Inc. (NASDAQ:EPZM – Get Rating).

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.